UWCCC Cancer Prevention and Control (CPC) Program Summary Co-Leaders: Hasan Mukhtar and Amy Trentham-Dietz PROJECT SUMMARY/ABSTRACT The Cancer Prevention & Control (CPC) Program spans basic, clinical, and population science to identify effective approaches to reduce the burden of cancer for patients, their families, and communities through improved prevention, early detection, and survival. In support of this overarching goal, the CPC program has defined three thematic aims. Theme 1: Identify promising chemopreventive targets and agents to test in clinical trials. Members build on a comprehensive integrated understanding of agents that decrease the incidence of cancer or its progression to clinically significant disease through drug development and clinical testing. Theme 2: Identify and implement effective approaches to reduce tobacco-related cancers. Members conduct intervention studies of innovative tobacco cessation approaches and lead observational cohort studies of real-world smoking patterns. Research focuses on underserved and minority populations since these are the same groups among whom the prevalence of smoking is greatest. Theme 3: Identify new strategies to improve the delivery of cancer care. Members identify effective approaches for delivering cancer screening and diagnostic tests and cancer therapies. CPC members are using innovative simulation modeling, bioinformatics, and multidisciplinary teams to improve the early detection of cancer; to leverage insights obtained through analysis of large databases to test approaches for improving access to guideline- concordant clinical care; and to incorporate patient-centered outcomes. CPC projects directly address the priorities present in the UWCCC catchment area and support reduction in cancer health disparities. The CPC Program has 33 members in 14 departments and 4 schools/colleges. Since 2012, CPC members have published 776 peer-reviewed manuscripts (25% intra-programmatic, 22% inter-programmatic). PIs were responsible for $11.1 million (direct costs) overall in peer-reviewed grant funding, with 60%, $6.7 million from NCI. Recent programmatic changes include new leadership, Dr. H. Mukhtar and Dr. A. Trentham-Dietz, and increased focus on interventions to reduce cancer and cancer risks in our communities. The CPC Program supports inter- and intra-programmatic interaction through pilot grants, seminars and retreats, a strong mentorship program, and collaborative working groups. Guided by strategic planning, priorities for the CPC program over the next 5 years include emphasizing cross-aim collaborations, building on existing momentum in health services research, and translational disparities research addressing needs in the UWCCC catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014520-44
Application #
9490024
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-30
Budget End
2019-03-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Jewett, Patricia I; Gangnon, Ronald E; Elkin, Elena et al. (2018) Geographic access to mammography facilities and frequency of mammography screening. Ann Epidemiol 28:65-71.e2
Pleiman, Jennifer K; Irving, Amy A; Wang, Zhishi et al. (2018) The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer. PLoS Genet 14:e1007611
Kletzien, Heidi; Macdonald, Cameron L; Orne, Jason et al. (2018) Comparison Between Patient-Perceived Voice Changes and Quantitative Voice Measures in the First Postoperative Year After Thyroidectomy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 144:995-1003
Kang, Lei; Jiang, Dawei; Ehlerding, Emily B et al. (2018) Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. Mol Pharm 15:1627-1634
Bulu, Hakan; Sippo, Dorothy A; Lee, Janie M et al. (2018) Proposing New RadLex Terms by Analyzing Free-Text Mammography Reports. J Digit Imaging 31:596-603
Jang, Samuel; Rosenberg, Stephen A; Hullet, Craig et al. (2018) Value of Elective Radiation Oncology Rotations: How Many Is Too Many? Int J Radiat Oncol Biol Phys 100:558-559
Albertini, Mark R (2018) The age of enlightenment in melanoma immunotherapy. J Immunother Cancer 6:80
Shull, James D; Dennison, Kirsten L; Chack, Aaron C et al. (2018) Rat models of 17?-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention. Physiol Genomics 50:215-234
Kang, Lei; Jiang, Dawei; England, Christopher G et al. (2018) ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging 45:1372-1381
Melgar-Asensio, Ignacio; Kandela, Irawati; Aird, Fraser et al. (2018) Extended Intravitreal Rabbit Eye Residence of Nanoparticles Conjugated With Cationic Arginine Peptides for Intraocular Drug Delivery: In Vivo Imaging. Invest Ophthalmol Vis Sci 59:4071-4081

Showing the most recent 10 out of 1528 publications